The Latest Breaking News from biotechnology

The technique could keep kidneys viable for longer and increase the number available for transplant.

A new U.K. bill is a chance at food security—if Britain can get past unfounded fears.

Key Takeaways: With no drug revenues and growing R&D costs, MingMed Biotechnology plans to feed its cash-burning machine with a Hong Kong IPO Company has seven drugs in development, including six in the clinical stages By Ellie Si

Thai food and agricultural companies are being advised to boost their productivity and food safety through the application of Internet of Things, robotics in value chains, and drone technology for plantation and agricultural biotechnology such as genetic engineering.

The Dow Jones dropped more than 600 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment…

Ahead of the visit of Uzbek President Shavkat Mirziyoyev to Saudi Arabia, the embassy of Uzbekistan in Riyadh expected a rapid and dynamic development of bilateral cooperation between the two countries. Cooperation is expected in the fields of energy, information technology, telecommunications, health, biotechnology and agriculture, in addition to forestry,…

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Leading biotechnology company Vertex Pharmaceuticals (VRTX) has achieved strong top and bottom-line growth in its last quarter. Furthermore, the company is well-positioned to benefit from its diversified pipeline of transformative small-molecule, cell, and genetic therapies. Thus, even after gaining 27.5% year-to-date, we think VRTX still has decent upside potential. Read…

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…